Published in Clin Dev Immunol on April 16, 2013
The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. Blood Transfus (2015) 0.82
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 13.59
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet (2007) 6.29
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer (1981) 4.25
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. J Exp Med (2011) 3.89
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 3.33
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood (2005) 3.14
BAFF: a fundamental survival factor for B cells. Nat Rev Immunol (2002) 2.94
Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med (1999) 2.89
B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol (1999) 2.60
How I treat autoimmune hemolytic anemias in adults. Blood (2010) 2.38
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med (1989) 2.16
Pure red cell aplasia. Br J Haematol (2000) 1.91
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood (2010) 1.86
Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood (2010) 1.79
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood (2000) 1.79
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol (2007) 1.76
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood (2001) 1.74
Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J (2006) 1.60
Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol (2006) 1.54
Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma (2012) 1.52
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma (2003) 1.50
Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. Leuk Lymphoma (2010) 1.48
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma (1993) 1.45
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood (2010) 1.34
Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia (2002) 1.29
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21
Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (2008) 1.20
Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. Clin Exp Immunol (1982) 1.14
Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica (2011) 1.14
Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol (1998) 1.13
Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep (2008) 1.10
B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood (1996) 1.10
Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood (2011) 1.09
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood (2007) 1.09
T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood (1978) 1.09
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol (2012) 1.08
Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol (2010) 1.07
Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. Blood (1982) 1.06
State of the art treatment of chronic lymphocytic leukaemia. Blood Rev (2010) 1.03
T gamma (T gamma) cells suppress growth of erythroid colony-forming units in vitro in the pure red cell aplasia of B-cell chronic lymphocytic leukemia. J Clin Invest (1982) 1.02
Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood (2004) 1.00
Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol (1986) 0.99
Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol (2011) 0.98
Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood (1993) 0.98
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol (1995) 0.98
Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol (2008) 0.95
Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol (2003) 0.94
Chronic lymphocytic leukemia-associated pure red cell aplasia. Int J Immunopathol Pharmacol (2009) 0.90
T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol (2010) 0.90
T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. Leuk Res (2002) 0.89
Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol (2012) 0.88
Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol (1996) 0.88
Pure red cell aplasia associated with B cell lymphoma: demonstration of bone marrow colony inhibition by serum immunoglobulin. Leuk Res (1990) 0.87
Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia (2010) 0.87
Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal. Blood (1987) 0.86
Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol (1998) 0.86
In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol (2002) 0.84
Hypoplastic anemia in B cell chronic lymphocytic leukemia: evolution of T cell-mediated suppression of erythropoiesis in early-stage and late-stage disease. Blood (1985) 0.84
Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia (2010) 0.83
Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol Suppl (1973) 0.83
Vaccine therapy and chronic lymphocytic leukaemia. Best Pract Res Clin Haematol (2008) 0.81
Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases. Mediterr J Hematol Infect Dis (2012) 0.81
Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol (1981) 0.80
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica (2010) 0.80
A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy? Curr Opin Oncol (2011) 0.80
Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol (2010) 0.79
Natural killer function in B-chronic lymphocytic leukemia. Nouv Rev Fr Hematol (1988) 0.78
Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma. Clin Rev Allergy (1992) 0.77
Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma (2007) 0.77
Na+/H+ antiporter has different properties in human B lymphocytes according to CD5 expression and malignant phenotype. Eur J Immunol (1991) 0.76
Autoreactive erythroid progenitor-T suppressor cells in the pure red cell aplasia associated with thymoma and panhypogammaglobulinemia. Am J Hematol (1986) 0.76
[Chronic B-cell lymphatic leukemia: autoimmune hemolytic anemias versus anemias caused by marrow failure]. Sangre (Barc) (1988) 0.76
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica (2012) 1.98
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma (2012) 1.77
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol (2010) 1.76
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer (2011) 1.67
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood (2009) 1.65
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma (2011) 1.60
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma (2007) 1.54
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol (2009) 1.54
Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet (2005) 1.53
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 1.47
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood (2007) 1.47
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol (2014) 1.44
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res (2011) 1.42
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. Leuk Res (2011) 1.39
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. Clin Adv Hematol Oncol (2012) 1.38
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 1.37
[Mainly abdominal "complex" polytrauma. Considerations on surgical strategy and clinical case report]. Ann Ital Chir (2006) 1.37
High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica (2006) 1.28
Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer (2007) 1.27
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol (2008) 1.23
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res (2010) 1.21
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Effect of essential oils on pathogenic bacteria. Pharmaceuticals (Basel) (2013) 1.20
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer (2011) 1.18
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res (2010) 1.11
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res (2013) 1.09
Chemical composition and antimicrobial activity of the essential oils from three chemotypes of Origanum vulgare L. ssp. hirtum (Link) Ietswaart growing wild in Campania (Southern Italy). Molecules (2009) 1.08
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol (2009) 1.07
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J (2004) 1.03
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res (2008) 1.03
Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther (2008) 1.03
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? J Clin Oncol (2012) 1.01
Compositional study and antioxidant potential of Ipomoea hederacea Jacq. and Lepidium sativum L. seeds. Molecules (2012) 1.00
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res (2013) 0.98
Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica (2002) 0.98
Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol (2012) 0.97
In-vitro and in-vivo validation of ethnopharmacological uses of methanol extract of Isodon rugosus Wall. ex Benth. (Lamiaceae). BMC Complement Altern Med (2014) 0.97
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol (2013) 0.97
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood (2013) 0.95
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer (2009) 0.95
Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res (2011) 0.94
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol (2012) 0.94
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol (2014) 0.93
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol (2012) 0.93
Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol (2013) 0.93
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol (2012) 0.92
In vitro control of post-harvest fruit rot fungi by some plant essential oil components. Int J Mol Sci (2012) 0.91
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer (2005) 0.91
Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol (2007) 0.91
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res (2011) 0.91
Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leuk Lymphoma (2013) 0.91
Medicinal and useful plants in the tradition of Rotonda, Pollino National Park, Southern Italy. J Ethnobiol Ethnomed (2013) 0.90
Chemical composition and antimicrobial activity of the essential oils from two species of Thymus growing wild in southern Italy. Molecules (2009) 0.90
Preservation of chicken breast meat treated with thyme and balm essential oils. J Food Sci (2010) 0.89
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol (2012) 0.88
Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Clin Cancer Res (2009) 0.88
Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol (2007) 0.88
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. Blood (2013) 0.87
Antioxidant activity of the extracts of some cowpea (Vigna unguiculata (L) Walp.) cultivars commonly consumed in Pakistan. Molecules (2013) 0.87
Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma. Leuk Lymphoma (2011) 0.86
Antinociceptive activity of cyclopeptide alkaloids isolated from Ziziphus oxyphylla Edgew (Rhamnaceae). Fitoterapia (2013) 0.86
Advanced mast cell disease: an Italian Hematological Multicenter experience. Int J Hematol (2008) 0.86
Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leuk Lymphoma (2004) 0.85
A pilot characterization of human lung NSCLC by protein pathway activation mapping. J Thorac Oncol (2012) 0.85
In vitro phytotoxicity and antioxidant activity of selected flavonoids. Int J Mol Sci (2012) 0.85
Chemistry, antioxidant, antibacterial and antifungal activities of volatile oils and their components. Nat Prod Commun (2009) 0.85
Chemical composition and biological activities of the essential oil from Calamintha nepeta plants from the wild in southern Italy. Nat Prod Commun (2013) 0.85
Quality of life and physicians' perception in myelodysplastic syndromes. Am J Blood Res (2012) 0.85
Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori (2014) 0.85
An attempt of postharvest orange fruit rot control using essential oils from Mediterranean plants. J Med Food (2010) 0.84